2. GPCR/G Protein
  3. Leukotriene Receptor
  4. Boc-Phe-Leu-Phe-Leu-Phe

Boc-Phe-Leu-Phe-Leu-Phe  (Synonyms: L-BOC2)

Cat. No.: HY-P3318 Purity: 98.03%
COA
SDS
Handling Instructions Technical Support

Boc-Phe-Leu-Phe-Leu-Phe (Boc-FLFLF) is a N-formyl peptide receptors (FPR) inhibitor. Boc-Phe-Leu-Phe-Leu-Phe abolishes the FMLP-induced release of peptide leukotrienes. Boc-Phe-Leu-Phe-Leu-Phe inhibits the sprouting of human umbilical vein endothelial cell (HUVEC) spheroids mediated by proliferative diabetic retinopathy (PDR) vitreous and vascular endothelial growth factor (VEGF) respectively in a three-dimensional fibrin gel. Boc-Phe-Leu-Phe-Leu-Phe inhibits the anti-inflammatory and antifibrotic effects of Ac2-26 (HY-P1098). Boc-Phe-Leu-Phe-Leu-Phe can be used for the study of immunology.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

Boc-Phe-Leu-Phe-Leu-Phe

Boc-Phe-Leu-Phe-Leu-Phe Chemical Structure

CAS No. : 73572-58-4

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Boc-Phe-Leu-Phe-Leu-Phe:

Boc-Phe-Leu-Phe-Leu-Phe Related Antibodies

Top Publications Citing Use of Products

View All Leukotriene Receptor Isoform Specific Products:

View All Isoforms
LTB4 LTC4/CysLT2 LTD4/CysLT1 LTE4

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Boc-Phe-Leu-Phe-Leu-Phe (Boc-FLFLF) is a N-formyl peptide receptors (FPR) inhibitor. Boc-Phe-Leu-Phe-Leu-Phe abolishes the FMLP-induced release of peptide leukotrienes. Boc-Phe-Leu-Phe-Leu-Phe inhibits the sprouting of human umbilical vein endothelial cell (HUVEC) spheroids mediated by proliferative diabetic retinopathy (PDR) vitreous and vascular endothelial growth factor (VEGF) respectively in a three-dimensional fibrin gel. Boc-Phe-Leu-Phe-Leu-Phe inhibits the anti-inflammatory and antifibrotic effects of Ac2-26 (HY-P1098). Boc-Phe-Leu-Phe-Leu-Phe can be used for the study of immunology[1][2][3][4][5].

In Vitro

Boc-Phe-Leu-Phe-Leu-Phe (0-50 μg/mL) inhibits the sprouting of HUVEC spheroids induced by PDR vitreous in a three-dimensional fibrin gel[1].
Boc-Phe-Leu-Phe-Leu-Phe (0-120 μM, 24 h) inhibits the sprouting of HUVEC spheroids mediated by VEGF in a dose-dependent manner[2].
Boc-Phe-Leu-Phe-Leu-Phe (100 ng/mL, 24 h) inhibits the ability of Ac2-26 (HY-P1098) to reduce the expression of TGF-β1, IL-1β, and IL-6 in LPS (HY-D1056)-induced RAW264.7 cells[4].
Boc-Phe-Leu-Phe-Leu-Phe (100 ng/mL, 24 h) blocks the inhibitory effect of Ac2-26 on the expression of α-SMA, collagen I, CTGF, and β-catenin in LPS-induced hepatic stellate cells (HSCs)[4].
Boc-Phe-Leu-Phe-Leu-Phe (10 µM) blocks the inhibitory effect of Ac2-26 on the increase of AnxA1 protein expression, phosphorylated NF-κB p65 levels, IκB-α degradation, and IL-8 production in A549 cells[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Boc-Phe-Leu-Phe-Leu-Phe Related Antibodies

Real Time qPCR[4]

Cell Line: LPS (HY-D1056)-induced RAW264.7 cells
Concentration: 100 ng/mL
Incubation Time: 24 h
Result: Reduced the expression of TGF-β1, IL-1β, and IL-6.

Western Blot Analysis[4]

Cell Line: LPS (HY-D1056)-induced RAW264.7 cells
Concentration: 100 ng/mL
Incubation Time: 24 h
Result: Reduced the expression of α-SMA, collagen I, CTGF, and β-catenin.
In Vivo

Boc-Phe-Leu-Phe-Leu-Phe (1 mg/kg, intraperitoneal injection, twice weekly for 4-8 weeks) reverses the anti-inflammatory and antifibrotic effects of Ac2-26 in wild-type mice and AnxA1 knockout mice with CCl4-induced liver fibrosis[4].
Boc-Phe-Leu-Phe-Leu-Phe (50 µg per rat, intraperitoneal injection 30 min before surgery, single dose) reverses the protective effects of Ac2-26 in rats with ischemia-reperfusion-induced acute lung injury[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Six-to-eight-week-old C57BL/6 wild-type mice and C57BL/6JGpt Anxa1-KO mice (weighing 18-25 g) were given intraperitoneal injection of 20% CCl4 (500 mL) twice weekly to induce liver fibrosis[4]
Dosage: 1 mg/kg
Administration: Intraperitoneal injection, twice weekly for 4/8 weeks
Result: Induced more severe liver lesions in CCl4-induced wild-type and AnxA1 knockout mice compared to Ac2-26 treatment, with lighter liver color, rougher surface, more nodules, and harder texture.
Increased liver inflammation and collagen deposition, as well as elevated expression of α-SMA, collagen I, CTGF, TGF-β1, IL-1β, IL-6, and β-catenin in liver tissues.
Reversed the anti-inflammatory and antifibrotic effects of Ac2-26, with the degree of liver damage and fibrosis similar to that in the CCl4-induced model group without Ac2-26 treatment.
Animal Model: Sprague-Dawley rats (male, 350 ± 20 g) were used to establish an isolated perfused lung model, with ischemia induced by stopping ventilation and perfusion for 40 min, followed by reperfusion for 60 min to induce ischemia-reperfusion lung injury[5]
Dosage: 50 µg per rat
Administration: Intraperitoneal injection 30 min before surgery for a single dose
Result: Abolished the protective effects of Ac2-26 in ischemia-reperfusion-induced acute lung injury in Sprague-Dawley rats, resulting in more severe lung edema, higher pulmonary arterial pressure, and increased protein concentration in bronchoalveolar lavage fluid.
Enhanced neutrophil infiltration, elevated levels of pro-inflammatory cytokines (CINC-1, TNF-α) in bronchoalveolar lavage fluid, and increased oxidative stress (higher protein carbonyl content and MDA level) and apoptosis (more activated caspase-3-immunolabeled cells, lower Bcl-2 expression) in lung tissue.
Aggravated lung tissue damage, with increased lung injury scores, disrupted tight junction proteins (claudin-3, occludin, ZO-1) in alveolar walls, and reversed the inhibition of NF-κB and MAPK pathways activation by Ac2-26.
Molecular Weight

785.97

Formula

C44H59N5O8
CAS No.
Appearance

Solid

Color

White to off-white

Sequence

{Boc}-Phe-Leu-Phe-Leu-Phe
Sequence Shortening

{Boc}-FLFLF
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Boc-Phe-Leu-Phe-Leu-Phe Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Boc-Phe-Leu-Phe-Leu-Phe73572-58-4L-BOC2Leukotriene Receptorleukotrienesvascular endothelial growth factorInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Boc-Phe-Leu-Phe-Leu-Phe
Cat. No.:
HY-P3318
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.